PATH | VRL
Menu

Recombinant Group B Streptococcus Beta C Protein and a Variant With the Deletion of its Immunoglobulin A-Binding Site Are Protective Mouse Maternal Vaccines and Effective Carriers in Conjugate Vaccines

This article, published in Infection and Immunity, reports the results of a study in mice that examined immunogenicity and protective efficacy of a recombinant group B Streptococcus beta C protein (rBCP), an rBCP modified to eliminate its immunoglobulin A-binding site, and their corresponding GBS serotype III capsular polysaccharide (CPS) conjugates. The authors suggest that the rBCP could be used as a carrier to augment the immunogenicity of the CPS while expanding coverage to GBS strains bearing BCP. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)

Author: Yang H-H, Madoff LC, Guttormsen H-K, Liu Y-D, Paoletti LC

Published: 2007

» Visit web page. (English)

(Located at iai.asm.org)

Citation: Yang H-H, Madoff LC, Guttormsen H-K, Liu Y-D, Paoletti LC. Recombinant Group B Streptococcus Beta C Protein and a Variant With the Deletion of its Immunoglobulin A-Binding Site Are Protective Mouse Maternal Vaccines and Effective Carriers in Conjugate Vaccines. Infection and Immunity. 2007;75(7):3455-3461. 

Resource types: Peer-reviewed journal

Diseases/vaccines: Group B Streptococcus (GBS)

Topics: Vaccine safety and performance, Disease/vaccine specific information, Vaccine stabilization and formulation

Regions: North America and Europe